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Abstract
Neisseria gonorrhoeae	causes	the	sexually	transmitted	disease	gonorrhea	exclusively	
in	humans	and	uses	multiple	strategies	to	infect,	including	acquisition	of	host	sialic	
acids	 that	 cap	and	mask	 lipooligosaccharide	 termini,	while	 restricting	complement	
activation.	We	hypothesized	that	gonococci	selectively	target	human	anti‐inflamma‐
tory	sialic	acid‐recognizing	Siglec	receptors	on	innate	immune	cells	to	blunt	host	re‐
sponses	and	that	pro‐inflammatory	Siglecs	and	SIGLEC	pseudogene	polymorphisms	
represent	 host	 evolutionary	 adaptations	 to	 counteract	 this	 interaction.	 N. gonor‐
rhoeae	 can	 indeed	 engage	multiple	 human	 but	 not	 chimpanzee	 CD33rSiglecs	 ex‐
pressed	on	innate	immune	cells	and	in	the	genitourinary	tract––including	Siglec‐11	
(inhibitory)	and	Siglec‐16	(activating),	which	we	detected	for	the	first	time	on	human	
cervical	epithelium.	Surprisingly,	in	addition	to	LOS	sialic	acid,	we	found	that	gono‐
coccal	porin	(PorB)	mediated	binding	to	multiple	Siglecs.	PorB	also	bound	preferen‐
tially	 to	 human	 Siglecs	 and	 not	 chimpanzee	 orthologs,	 modulating	 host	 immune	
reactions	 in	 a	 human‐specific	 manner.	 Lastly,	 we	 studied	 the	 distribution	 of	 null	
SIGLEC polymorphisms	in	a	Namibian	cohort	with	a	high	prevalence	of	gonorrhea	and	
found	that	uninfected	women	preferentially	harbor	functional	SIGLEC16 alleles en‐
coding	an	activating	immune	receptor.	These	results	contribute	to	the	understanding	
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1  | INTRODUC TION
Gonorrhea	 is	 a	 sexually	 transmitted	 disease	 that	 poses	 a	 major	
global	 health	 problem,	 with	 about	 78	million	 estimated	 infections	
worldwide	in	2012	(Newman	et	al.,	2015).	This	disease	is	caused	by	
Neisseria gonorrhoeae,	 a	 Gram‐negative	 bacterium	 that	 exclusively	
infects	humans.	Urogenital	epithelia	are	the	main	sites	of	infection,	
but	N. gonorrhoeae	can	also	infect	the	conjunctiva,	pharynx,	and	rec‐
tal	mucosa	(Edwards	&	Apicella,	2004).	Gonococci	successfully	pro‐
liferate	 in	different	host	microenvironments	and	evade	the	human	
immune	 system	 by	 constantly	 modulating	 their	 surface	 antigenic	
makeup	by	phase	variation	and	other	mechanisms	(Criss	&	Seifert,	
2012;	Edwards	&	Apicella,	2004;	Virji,	2009).
Dynamic	changes	in	the	glycan	extensions	of	gonococcal	lipooli‐
gosaccharide	(LOS)	are	an	excellent	example	of	how	N. gonorrhoeae 
evade	the	host	 immune	response.	The	 lacto‐N‐neotetraose	 (LNnT)	
structure	of	the	LOS	engages	host	surface	receptors,	 like	the	asia‐
loglycoprotein	receptor	 (ASGP‐R),	and	 leads	to	the	 invasion	of	the	
urethral	epithelia	(Harvey,	Jennings,	Campbell,	Williams,	&	Apicella,	
2001).	 Sialic	 acid,	 a	 9‐carbon	 backbone	 acidic	 sugar,	 plays	 an	 im‐
portant	 role	 during	 the	 infection	 of	 many	 human‐specific	 patho‐
gens	(Hentrich	et	al.,	2016;	Patrone	&	Stein,	2007;	Varki	&	Gagneux,	
2012).	 The	 gonococcal	 LNnT	 structure	 becomes	 sialylated	 by	 the	
gonococcal	 sialyltransferase	 (Lst),	 a	 surface‐exposed	 outer	 mem‐
brane	 protein	 that	 uses	 host	 sialic	 acid	 in	 form	 of	 CMP‐Neu5Ac	
(Shell,	Chiles,	Judd,	Seal,	&	Rest,	2002).	Sialylation	helps	the	bacteria	
recruit	factor	H	to	become	more	resistant	to	complement‐mediated	
killing	 (Ram	et	al.,	1998,	1999)	and	blocks	antibody	 recognition	of	
select	underlying	structures	(Elkins	et	al.,	1992).
Sialic	 acids	 on	mammalian	 cell	 surfaces	 are	 also	 recognized	 as	
“Self‐Associated	Molecular	Patterns”	(SAMPs)	by	other	receptors	of	
the	host	immune	system	(Varki,	2011).	Interactions	of	sialylated	host	
glycans	with	inhibitory	members	of	the	sialic	acid‐binding	immuno‐
globulin	superfamily	lectins	(Siglecs)	maintain	immune	cells	in	a	qui‐
escent	state	and	dampen	unwanted	inflammation	(Crocker,	Paulson,	
&	Varki,	2007;	Varki,	2011;	von	Gunten	&	Bochner,	2008).	Inhibitory	
effects	 are	 driven	 by	 ITIM	 motifs	 in	 Siglec	 intracellular	 domains,	
which	recruit	SHP	phosphatases	and	quench	pro‐inflammatory	sig‐
naling	cascades.	This	property	is	subverted	by	pathogens	to	control	
host	immune	responses	and	escape	elimination.	For	example,	group	
B	streptococci	(GBS)	evade	host	immune	responses	by	engaging	in‐
hibitory	Siglec‐5	and	Siglec‐9	(Carlin,	Lewis,	Varki,	&	Nizet,	2007).
However,	humans	also	express	paired	Siglecs––sets	of	receptors	
with	 similar	 ligand	 specificities	 but	 opposite	 signaling	 properties.	
For	 instance,	the	Siglec‐5/‐14	and	Siglec‐11/‐16	pairs	have	a	highly	
conserved	 extracellular	 domain	 and	 similar	 ligand	 specificities	
(Angata,	 Hayakawa,	 Yamanaka,	 Varki,	 &	 Nakamura,	 2006;	 Cao	 et	
al.,	2008;	Schwarz,	Fong,	&	Varki,	2015;	Wang,	Mitra,	Cruz,	et	al.,	
2012).	Activating	Siglecs	recruit	adaptor	proteins	such	as	DAP10	and	
DAP12	 through	a	positively	 charged	amino	acid	 in	 the	 transmem‐
brane	domain	(Angata	et	al.,	2006;	Cao	et	al.,	2008;	Pillai,	Netravali,	
Cariappa,	&	Mattoo,	2012;	Tourdot	et	al.,	2013).	The	adaptor	pro‐
teins	contain	 ITAM	motifs	that	recruit	Syk	kinase,	which	 induces	a	
pro‐inflammatory	signaling	cascade	(Lanier,	2009).	It	has	been	sug‐
gested	 that	activating	Siglecs	 represent	evolutionary	 responses	 to	
microbes	 exploiting	 inhibitory	 Siglecs.	 In	 fact,	 Siglec‐14	 has	 been	
shown	to	counteract	the	exploitation	of	Siglec‐5	by	GBS	(Ali	et	al.,	
2014),	 and	Siglec‐16	 reduces	 survival	of	E. coli K1	during	 infection	
(Schwarz	et	al.,	2017).	Moreover,	due	to	polymorphic	pseudogeniza‐
tion,	not	all	humans	are	able	to	express	these	activating	Siglec	recep‐
tors,	generating	different	immune	responses	to	infections	(Angata	et	
al.,	2013;	Schwarz	et	al.,	2015).	Notably,	in	some	instances,	Siglec‐14	
blocking	antibody	reversed	pathogens	have	also	evolved	direct	 in‐
teractions	of	Siglecs	with	their	surface	proteins	(Carlin	et	al.,	2009).	
In	this	study,	we	elucidate	how	N. gonorrhoeae	has	evolved	both	si‐
alic	 acid‐dependent	 and	 sialic	 acid‐independent	 interactions	 with	
human	 but	 not	 chimpanzee	 Siglecs	 to	 modulate	 their	 pathogenic	
potential	and	the	host	 inflammatory	response	 in	a	species‐specific	
manner,	thus	contributing	to	the	host	restriction	of	gonorrhea.	We	
also	explore	the	impact	of	Siglec	polymorphisms	in	a	population	at	
high	risk	of	gonorrhea.
2  | MATERIAL S AND METHODS
2.1 | Bacteria and cell lines
Neisseria gonorrhoeae	 F62	was	 isolated	 from	 an	 uncomplicated	 in‐
fection	(Kellogg,	Peacock,	Deacon,	Brown,	&	Pirkel,	1963).	Neisseria 
gonorrhoeae	 15253	 was	 isolated	 from	 a	 disseminated	 infection	
(O'Brien,	Goldenberg,	&	Rice,	1983).	Both	strains	were	piliated.	The	
mutant	 strains	 of	 F62	 (ΔlgtD,	ΔlgtA,	ΔlgtE,	 and	ΔlgtF)	were	 con‐
structed	using	plasmids	and	methods	described	previously	(Gulati	et	
al.,	2015).	The	LOS	phenotype	of	the	mutants	was	verified	by	LOS	
staining	of	protease	K‐treated	whole‐cell	 samples	 that	were	 sepa‐
rated	on	a	12%	Bis–Tris	gel	with	MES	running	buffer.	N. gonorrhoeae 
were	grown	overnight	on	chocolate	agar	plates	with	IsoVitaleX	(BD	
Bioscience)	 or	 in	GC	broth	 supplemented	with	 IsoVitaleX	 at	 37°C	
and	5%	CO2.	When	indicated,	growth	media	was	supplemented	with	
of	the	human	specificity	of	N. gonorrhoeae and	how	it	evolved	to	evade	the	human	
immune	defense.
K E Y W O R D S
disease	biology,	evolutionary	medicine,	gonorrhea,	microbial	biology,	polymorphism,	
population	genetics,	sialic	acid,	Siglecs
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30	µM	CMP‐Neu5Ac	 (Nacalai	USA,	 Inc.).	 Incorporation	of	Neu5Ac	
has	 been	 confirmed	 by	 loss	 of	 Erythrina	 Cristagalli	 Lectin	 (ECA,	
Vector	Laboratories),	which	binds	to	the	lactosamine	epitope.	For	all	
binding	and	infection	studies,	bacteria	were	cultivated	to	an	optical	
density	at	600	nm	equivalent	to	0.4–0.6.	THP‐1	cells	were	grown	in	
RPMI‐1640	(Gibco)	with	10%	fetal	calf	serum	(Gemini	Bio‐Products)	
at	37°C	and	5%	CO2.
2.2 | Siglec‐Fc production
Siglec‐Fcs	 were	 produced	 as	 described	 in	 Padler‐Karavani	 et	 al.	
(2014).	 Siglec‐Fc	 vectors	 were	 transfected	 into	 HEK293A	 cells	
cultured	 in	 serum‐free	 media	 supplemented	 with	 Nutridoma‐SP	
(Roche).	Culture	 supernatants	were	collected,	and	Siglec‐Fcs	were	
purified	 on	 a	 Sepharose	 Protein	 A	 Column	 (GE	 Healthcare	 Life	
Sciences).	After	washing	with	Tris‐buffered	saline	(20	mM	Tris–HCl,	
150	mM	NaCl,	pH	8.0;	TBS),	Siglec‐Fcs	were	desialylated	on	column	
by	neuraminidase	from	Arthrobacter	ureafaciens	(Sigma‐Aldrich)	for	
1	hr	at	room	temperature.	After	extensive	washing	with	TBS,	Siglec‐
Fcs	were	eluted	with	0.1	M	glycine–HCl	pH	3.0	and	pH	is	neutral‐
ized	immediately.	Siglec‐Fcs	are	concentrated	by	Amicon	centrifugal	
filters	(Millipore).	The	functionality	of	Siglec‐Fcs	has	been	pretested	
on sialoglycan arrays.
2.3 | Bacteria binding assay
Ninety‐six‐well	plates	were	coated	with	1	μg/well	protein	A	(Thermo	
Scientific)	in	50	mM	carbonate	buffer	pH	9.5	overnight	at	4°C.	Wells	
were	 washed	 with	 PBS‐T	 (0.05%	 Tween‐20	 in	 PBS)	 and	 blocked	
with	1%	BSA	in	PBS	for	1	hr	at	room	temperature.	1	μg/well	Siglec‐
Fcs	 were	 incubated	 for	 2	hr	 at	 room	 temperature.	 To	 correct	 for	
unspecific	 binding	 of	 Fc	 part,	 human	 IgG	was	 incubated	 in	 paral‐
lel.	Afterward,	wells	were	washed	with	PBS‐T.	N. gonorrhoeae were 
pelleted,	 washed	with	 HBSS,	 and	 then	 incubated	with	 0.1%	 fluo‐
rescein	 isothiocyanate	 (FITC,	 Sigma)	 in	PBS	 for	1	hr	 at	37	 ˚C	with	
rotation.	 Bacteria	were	 extensively	washed	with	HBSS	 to	 remove	
trace	 amounts	 of	 free	 FITC	 and	 then	 resuspended	 in	HBSS	 at	 an	
optical	density	of	1	at	600	nm.	A	volume	of	0.1	ml	of	FITC‐labeled	
bacteria	was	added	to	each	well.	Plates	were	centrifuged	at	500	g	for	
10	min	and	incubated	for	1	hr	at	room	temperature.	After	washing	
to	remove	unbound	bacteria,	the	residual	fluorescent	intensity	was	
measured	using	a	SpectraMax	M3	 (Molecular	Devices).	Unspecific	
binding	signal	from	human	IgG	was	subtracted	as	background	from	
data.	Binding	of	Siglec‐Fc	to	N. gonorrhoeae	was	performed	by	incu‐
bating	~107	bacteria	with	the	indicated	concentrations	of	Siglec‐Fc	
for	30	min	at	37°C.	Bound	Siglec‐Fc	was	detected	with	anti‐human	
IgG	FITC	on	a	FACSCalibur,	 and	data	were	 analyzed	using	FlowJo	
software.
2.4 | Binding assays to porins
Ninety‐six‐well	 plates	 were	 coated	 with	 1	μg/well	 of	 purified	
PorinB.1A	 and	 PorinB.1B.	 Purified	 porins	 are	 in	 their	 native	 trim‐
eric	state	in	proteosomes	and	purified	as	described	in	Ref.	Massari,	
F I G U R E  1  Siglec‐11	and	Siglec‐16	are	expressed	on	human	
cervical	epithelium.	Immunohistochemical	analysis	of	paraffin	
sections	of	human	cervix	samples,	with	spleen	as	positive	control	
using	mouse	monoclonal.	(a)	anti‐Siglec‐11	and	(b)	anti‐Siglec‐16	
antibodies	(green).	Nuclei	are	blue	(Hoechst),	red	arrows	indicate	
columnar	cervical	epithelium,	and	yellow	bar	indicates	100	µm.	
Images	are	representative	of	n	=	3.	The	samples	of	human	Cervix	
and	spleen	shown	were	heterozygous	for	SIGLEC16
F I G U R E  2  Human	Siglecs	bind	selectively	to	Neisseria 
gonorrhoeae.	Recombinant	human	and	chimpanzee	Siglec‐Fc	fusion	
proteins	were	immobilized,	and	binding	of	FITC‐labeled,	sialylated	
N. gonorrhoeae	(a)	strain	F62	and	(b)	strain	15253	was	measured.	
Binding	is	normalized	to	human	Siglec‐3‐Fc	and	corrected	for	
unspecific	binding	to	Fc	part	(huIgG).	Data	were	analyzed	with	t 
test	and	represented	as	mean	±	SD,	n = 3
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King,	MacLeod,	and	Wetzler	 (2005)	or	purified	 IgA‐Br	as	negative	
control	(Fong	et	al.,	2015)	in	50	mM	carbonate	buffer	pH	9.5	over‐
night	 at	 4°C.	Wells	were	washed	with	 PBS‐T	 (0.05%	Tween‐20	 in	
PBS)	 and	 blocked	with	 1%	BSA	 in	 PBS	 for	 1	hr	 at	 room	 tempera‐
ture.	Wells	were	washed	and	incubated	with	5	µg/ml	Siglec‐Fc	in	1%	
BSA	PBS‐T	 for	2	hr	at	 room	 temperature.	Wells	were	washed	and	
incubated	with	goat	HRP‐conjugated	anti‐human	IgG	(1:5,000	dilu‐
tion,	 Jackson	 ImmunoResearch	 Laboratories	 Inc.)	 for	 1	hr	 at	 room	
temperature.	Wells	were	washed	and	incubated	with	TMB	substrate	
(BD	OptEIA),	and	absorbance	was	measured	using	a	SpectraMax	M3	
(Molecular	Devices).
2.5 | Cytokine secretion analysis
THP‐1	 cells	 expressing	 Siglec‐5	 or	 Siglec‐14	 (Yamanaka,	 Kato,	
Angata,	&	Narimatsu,	2009)	were	differentiated	with	10	ng/ml	PMA	
in	a	24‐well	plate	for	24	hr	and	infected	with	MOI	=	1	of	the	same	
inoculum	 of	 N. gonorrhoeae	 F62.	 Supernatant	 was	 collected	 after	
24	hr.	IL‐6	concentration	was	measured	with	ELISA	standard	kit	from	
BioLegend.
2.6 | Phagocytosis assay
THP‐1	 cells	 transduced	 with	 an	 expression	 plasmid	 for	 Siglec‐5,	
Siglec‐14,	 or	 empty	 vector	were	 differentiated	with	 12.5	ng/ml	 of	
phorbol	 myristate	 acetate	 (PMA)	 for	 24	hr.	 Next,	 the	 cells	 were	
washed	with	sterile	culture	media,	blocking	or	nonblocking	antibod‐
ies	were	 added,	 and	 then	 exposed	 to	 10	µg/ml	 of	 PIB	 for	 10	min	
before	the	addition	of	pHrodo	Red	S. aureus	BioParticles	(prepared	
as	per	manufacturer's	instructions,	Thermo	Fisher	Scientific).	After	
incubation	 at	 37°C	 for	 2	hr,	 the	 cells	 were	washed	with	 PBS	 and	
then	 detached	with	 5	mM	EDTA	 in	 PBS.	 The	 detached	 cells	were	
centrifuged	for	5	min	at	500	g	and	washed	with	PBS.	After	another	
centrifugation,	 the	cells	were	resuspended	 in	PBS	and	assayed	for	
F I G U R E  3  Siglec	interactions	with	
gonococci	are	sialic	acid‐dependent	
and	sialic	acid‐independent.	The	LNnT	
LOS	(a)	of	N. gonorrhoeae F62	strain	can	
be	sialylated	by	the	sialyltransferase	
(Lst)	in	the	presence	of	CMP‐Neu5Ac.	
Phase‐variable	genes	are	presented	
in	gray.	(b)	Binding	FITC‐labeled	F62	
grown	with	and	without	CMP‐Neu5Ac	to	
immobilized	human	Siglec‐Fcs.	Binding	
is	normalized	to	human	Siglec‐3‐Fc	and	
corrected	for	unspecific	binding	to	Fc	
part	(huIgG).	Data	were	analyzed	with	t 
test	and	represented	as	mean	±	SD,	n = 3. 
(c–g)	Binding	of	human	Siglec‐Fcs	to	F62	
mutants	where	genes	that	encoded	the	
glycosyltransferases	lgtD,	lgtA,	lgtE, or lgtF 
were	deleted,	which	lead	to	progressive	
truncation	of	the	LOS,	was	measured	by	
flow	cytometry.	Bacteria	(~107	CFU)	were	
incubated	with	10	µg/ml	of	each	Siglec‐Fc	
for	15	min	at	37°C	and	surface‐bound	
Siglec‐Fcs	were	detected	with	anti‐human	
IgG	(Fc	specific)	conjugated	to	FITC.	
Controls	represent	bacteria	incubated	
with	anti‐human	IgG	FITC	alone	(no	
added	Siglec‐Fc).	Data	are	represented	as	
mean	±	SEM,	n = 3
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phagocytosis	of	the	pHrodo	BioParticles	by	flow	cytometry.	All	tests	
were	performed	in	triplicate.
2.7 | Immunohistochemistry
Samples	 used	 for	 immunohistochemistry	 were	 heterozygous	 for	
Siglec‐16	 or	 homozygous	 null	 (negative	 control).	 All	 three	 human	
cervix	 samples	 that	 were	 used	 had	 both	 squamous	 epithelium	
and	 columnar	 epithelium	 as	 well	 as	 the	 junctional	 zone.	 Samples	
of	 human	 spleen	 similarly	 either	 heterozygous	 for	 Siglec‐16	 (posi‐
tive	control)	or	homozygous	null	 (negative	control)	were	used	with	
every	experiment.	Deparaffinized	sections	were	blocked	for	endog‐
enous	 peroxidases	 and	 endogenous	 biotin	 and	 subjected	 to	 heat‐
induced	antigen	 retrieval	using	pH	9.0	buffer	and	pressure	cooker	
de‐cloaking	chamber	 (Biocare	Medical)	 for	15	min	at	110	degrees.	
After	 the	 slides	 cooled	 to	 37°C,	 the	 sections	 were	 overlaid	 with	
primary	antibodies	at	 the	appropriate	dilutions	and	 incubated	 in	a	
humid	chamber	overnight	at	4°C.	Following	washing	after	each	in‐
cubation,	the	sections	were	sequentially	overlaid	with	biotinylated	
anti‐mouse,	HRP‐Streptavidin,	and	biotinyl	tyramide	to	amplify,	ei‐
ther	 HRP‐Streptavidin	 again	 or	 fluorescently	 labeled	 streptavidin.	
If	HRP‐Streptavidin	was	the	final	step,	the	substrate	used	for	color	
development	was	AEC	(Vector	 laboratories)	and	nuclei	were	coun‐
terstained	with	Mayer's	 hematoxylin	 and	 the	 slides	were	 aqueous	
mounted	for	viewing	and	photography	using	a	Olympus	Magnafire	
digital	 photomicrography	on	 an	Olympus	BH2	 light	microscope.	 If	
fluorescence	tags	were	used,	the	nuclei	were	counterstained	using	
Hoechst	and	coverslipped	and	viewed	with	photography	using	the	
Keyence	BZ9000	with	the	appropriate	filters.
2.8 | Genotyping of Siglecs in Namibian cohort
Genomic	 DNA	 was	 isolated	 from	 FTA	 cards	 of	 Namibian	 cohort	
(Hazel,	Ponnaluri‐Wears,	Davis,	Low,	&	Foxman,	2014)	with	E.Z.N.A.	
MicroElute	 Genomic	 DNA	 Kit	 (OMEGA).	 The	 participants	 of	 the	
Namibian	cohort	 study	were	 randomly	 selected	and	not	based	on	
any	reported	symptoms.	Genotyping	of	the	Siglec‐3	polymorphism	
rs3865444	was	 performed	 as	 described	 in	 Schwarz	 et	 al.	 (2016).	
Genotyping	of	Siglec‐5	and	Siglec‐14	was	performed	as	described	in	
Yamanaka	et	al.	(2009).	Genotyping	of	Siglec‐16	was	performed	by	PCR	
with	 primers	 (forward:	 GCATGTCTGATCACCTCAGTTGGGAAAG;	
reverse:	 CCCTGACTCTCCTGTACTGATAAACC)	 and	 OneTaq	
MasterMix	 (New	 England	 Biolabs).	 Followed	 by	 restriction	 digest	
with	 TspRI	 (New	 England	 Biolabs),	 which	 cuts	 a	 polymorphism	
(Wang,	 Mitra,	 Secundino,	 et	 al.,	 2012)	 in	 disequilibrium	 with	 the	
SIGLEC16P.
2.9 | Statistical analysis
Prism	 6	 software	 (GraphPad)	 was	 used	 for	 statistical	 analyses	 of	
binding,	 cytokine,	 and	 phagocytosis	 assays.	 Quantitative	 data	 are	
expressed	as	means	 ± 	standard	deviation	(SD,	represented	as	error	
bars).	Unpaired	Student's	t	test	or	ANOVA	was	used	for	comparisons	
involving	two	groups.
Gene	 Association	 Analysis:	 Gene–disease	 association	 was	 as‐
sessed	between	binary	 variables	 representing	 each	genotype	 (ho‐
mozygous	 dominant,	 heterozygous,	 homozygous	 recessive)	 of	 the	
three	loci	(Siglec‐3,	Siglec‐16,	and	Siglec‐5/14),	and	we	used	models	
considering	 the	 presence	 or	 absence	 of	 each	 genotype.	 Standard	
genetic	models	of	dominant,	recessive,	additive,	and	epistatic	were	
examined	but	discarded	due	to	overfitting.	The	unusually	high	fre‐
quency	 of	 disease	 mutations	 seen	 in	 Namibian	 cohort	 interfered	
with	 the	 efficacy	 of	 common	 models.	 Binary	 genotype	 variables	
were	used	instead.	These	models	are	sufficient	to	assess	univariate	
and	bivariate	gene–disease	associations	provided	two	genotype	vari‐
ables	corresponding	to	one	gene	are	not	used	in	the	same	model;	this	
results	in	nonexistent	genome	models	and	therefore	was	avoided.
Models	were	 learned	 from	gender‐segregated	 data	 to	 account	
for	the	unique	mechanisms	of	virulence	across	genders.	Univariate	
logistic	regressions	were	constructed	to	predict	the	magnitude	and	
significance	of	association	between	each	genotype	and	the	disease.	
The	univariate	models	provided	assessments	of	the	single	genotype	
contributions	to	the	disease.	Multivariate	additive	was	constructed	
using	the	R::MASS::stepAIC	function.	Multivariate	additive	models	
F I G U R E  4  Siglecs	bind	to	the	gonococcal	porin	in	a	human‐
specific	manner.	Purified	PorinB.1A	from	15253	(a)	and	PorinB.1B	
from	F62	(b)	were	immobilized,	and	binding	of	human	and	
chimpanzee	Siglec‐Fc	proteins	was	detected	with	anti‐human	
IgG‐HRP	(Fc	specific).	Data	were	corrected	for	unspecific	
binding	to	BSA	and	represented	as	mean	±	SD,	n	=	3,	p‐values	for	
PorinB.1A	and	PorinB.1B,	respectively,	Siglec‐5	p	=	0.002/0.009,	
Siglec‐9	p	<	0.001/<0.001,	Siglec‐11	p	=	0.023/0.006,	Siglec‐14	
p	<	0.001/=0.001,	and	Siglec‐16	p	<	0.001/=0.006)
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were	constructed	using	backward	selection	from	the	complete	addi‐
tive	model	including	all	genotypes.	Code	is	deposited	at	github.com/
bkellman/Gh_genotypes/.
3  | RESULTS
3.1 | Siglec‐11 and Siglec‐16 are expressed on 
human cervical epithelium
Siglecs	are	mainly	found	on	cells	of	the	innate	immune	system:	For	
example,	monocytes	express	Siglec‐3	and	Siglec‐9;	neutrophils	ex‐
press	Siglec‐5,	Siglec‐9,	and	Siglec‐14	(Crocker	et	al.,	2007);	and	mac‐
rophages	 express	 Siglec‐3,	 Siglec‐11,	 and	 Siglec‐16.	 Some	 Siglecs	
also	 have	 been	 found	 on	 other	 cell	 types;	 for	 example,	 Siglec‐11	
on	 ovarian	 fibroblasts	 (Wang	 et	 al.,	 2011),	 Siglec‐5	 on	 human	 but	
not	chimpanzee	amniotic	epithelia	(Ali	et	al.,	2014),	and	Siglec‐6	on	
human	placental	 trophoblast,	but	not	 in	great	apes	 (Brinkman‐Van	
der	 Linden	 et	 al.,	 2007).	 The	 primary	 site	 of	 gonococcal	 infection	
in	 women	 is	 the	 endocervical	 epithelium.	 We	 detected	 Siglec‐11	
and	 Siglec‐16	 expression	 on	 human	 cervical	 columnar	 epithelium	
(Figure	1),	but	not	Siglec‐3,	Siglec‐5,	Siglec‐9,	and	Siglec‐14	(data	not	
shown).	Cervical	squamous	epithelia	did	not	show	any	Siglec‐11	or	
Siglec‐16	expression	(data	not	shown).	The	presence	of	Siglec‐11	and	
Siglec‐16	on	the	cervical	columnar	epithelium,	the	main	site	of	gono‐
coccal	infection	in	females,	may	play	a	crucial	role	in	host	defense.	
We	hypothesize	that	N. gonorrhoeae engages	the	inhibitory	Siglec‐11,	
which	 downregulates	 the	 pro‐inflammatory	 response	 and	 enables	
the	 bacteria	 to	 escape	 immune	 detection	 and	 establish	 asympto‐
matic	infection.	Siglec‐11	is	expressed	in	all	humans;	however,	due	to	
a	polymorphism,	not	all	humans	are	able	to	express	Siglec‐16	(Wang,	
Mitra,	Cruz,	et	al.,	2012).	In	individuals	who	express	this	activating	
receptor,	Siglec‐16	could	enable	 the	host	 to	detect	N. gonorrhoeae 
and	 mount	 a	 pro‐inflammatory	 immune	 response	 that	 results	 in	
symptoms	and	facilitates	clearance	of	bacteria.
3.2 | Neisseria gonorrhoeae selectively engages 
human Siglec receptors
Natural	infection	with	N. gonorrhoeae occurs	exclusively	in	humans.	
Siglecs	 are	 widely	 expressed	 on	 cell	 surfaces	 of	 innate	 immune	
cells	 such	as	macrophages	and	neutrophils,	which	produce	key	 in‐
nate	 immune	 responses	 to	gonococcal	 infections	 (Virji,	2009).	We	
focused	on	Siglecs	3,	5,	9,	11,	14,	and	16,	which	are	prominent	ex‐
amples	 of	 Siglecs	 expressed	 by	 phagocytes	 and/or	 epithelial	 cells	
that	are	relevant	to	gonococcal	 infection	 in	humans.	To	determine	
whether	gonococci	 interact	with	Siglecs	 in	 a	human‐specific	man‐
ner	that	may	contribute	to	its	human	specificity,	we	compared	bind‐
ing	 of	 recombinant	 soluble	 extracellular	 domains	 of	 human	 and	
chimpanzee	 homologs	 (fused	with	 Ig‐Fc)	 to	N. gonorrhoeae	 strains	
F62	and	15253	 (Figure	2).	While	 strain	F62	can	express	 the	LNnT	
LOS	epitope	 that	 can	be	 terminally	 substituted	with	 sialic	 acid	via	
an α2‐3	 linkage	 (Yamasaki,	Nasholds,	Schneider,	&	Apicella,	1991),	
strain	15253	lacks	the	genes	that	encode	LOS	glycosyltransferases	
LgtB,	LgtC,	and	LgtD	(Erwin,	Haynes,	Rice,	&	Gotschlich,	1996)	and	
thus	 can	 expresses	 LOS	 structures	 with	 only	 lactose	 extensions	
from	HepI	and	HepII	(Supporting	Information	Figure	S6a)	(Mandrell,	
Griffiss,	 Smith,	 &	 Cole,	 1993).	While	 human	 Siglec‐3	 (also	 known	
as	CD33)	bound	strongly	to	strain	F62	(grown	in	media	containing	
CMP‐Neu5Ac	 to	 sialylate	 LOS,	 Supporting	 Information	Figure	 S1),	
the	chimpanzee	homolog	showed	no	binding	(p	=	0.002;	Figure	2a).	
F62	bound	to	all	other	human	and	chimpanzee	Siglecs	tested	(Siglecs	
5,	9,	11,	14,	and	16),	with	human	Siglec‐11	(p	=	0.013)	and	Siglec‐14	
(p	=	0.010)	 also	 showing	a	 significantly	 increased	binding	over	 the	
chimpanzee	 homologs.	 The	 N. gonorrhoeae PorB.1A	 strain	 15253,	
which	 was	 isolated	 from	 a	 disseminated	 infection,	 bound	 signifi‐
cantly	 better	 to	 human	 Siglec‐3	 (p	=	0.037),	 Siglec‐5	 (p	=	0.011),	
Siglec‐9	(p	=	0.009),	and	Siglec‐14	(p	=	0.002)	than	to	its	chimpanzee	
homolog	 (Figure	2b).	The	LOS	of	strain	15253	present	 in	bacterial	
Triton	X‐100	extracts	can	be	sialylated	upon	addition	of	3H‐labeled	
CMP‐Neu5Ac	(Mandrell,	Smith,	Jarvis,	McLeod,	&	Cole,	1993).	We	
recently	confirmed	the	addition	of	Neu5Ac	to	the	lactose	extension	
from	HepII	on	intact	bacteria	when	strain	15253	was	grown	in	the	
presence	of	CMP‐Neu5Ac	(Ram	et	al.,	2018).
F I G U R E  5  Siglec‐5	and	Siglec‐14	modulate	pro‐inflammatory	
response	in	opposite	directions.	(a)	The	secretion	of	pro‐
inflammatory	cytokine	IL‐6	was	measured	in	THP‐1	expressing	
either	Siglec‐5	or	Siglec‐14	after	incubation	with	F62	for	24	hr.	
(b)	Phagocytic	activity	of	THP‐1	cells	expressing	Siglec‐14	was	
measured	by	adding	PorB.1B	and	monitoring	the	uptake	of	
fluorescent	particles	(pHrodo).	A	blocking	anti‐Siglec‐14	antibody	
could	reverse	the	uptake.	Data	are	represented	as	mean	±	SD,	n = 3
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Amino	acid	sequence	differences,	as	well	as	differences	in	post‐
translational	modifications	such	as	N‐	and	O‐glycosylation	between	
the	 human	 and	 chimpanzee	 homologs,	 could	 be	 responsible	 for	
the	 difference	 in	 binding	 (Supporting	 Information	 Figures	 S2–S5).	
Differences	 in	patterns	of	Siglec	binding	between	 the	 strains	may	
also	be	due	to	differences	in	the	LOS	structure	(Figure	3a),	 includ‐
ing	 sialylation,	 and/or	 other	 surface	 structures	 that	 could	 modify	
interactions.
3.3 | Neisseria gonorrhoeae binding to Siglecs is 
only partially dependent on LOS sialic acid, and 
truncation of LOS increases binding
Since	Siglecs	are	lectins	that	usually	bind	to	sialic	acid,	we	hypoth‐
esized	that	the	sialylated	LOS	on	N. gonorrhoeae (Figure	3a)	is	likely	
the	 primary	 ligand	 for	 Siglecs.	Growth	 of	N. gonorrhoeae in media 
lacking	CMP‐Neu5Ac	leads	to	expression	of	non‐sialylated	LOS	be‐
cause	 gonococci	 lack	 the	 ability	 to	 synthesize	 sialic	 acid	 de	 novo; 
the	addition	of	CMP‐Neu5Ac	to	media	results	in	sialylation	of	LNnT	
LOS	 (Mandrell,	 Smith,	 et	 al.,	 1993;	 Nairn	 et	 al.,	 1988;	 Supporting	
Information	Figure	S1).	The	binding	of	sialylated	and	non‐sialylated	
gonococci	 F62	 indeed	 differs	 with	 some	 Siglecs	 (Figure	 3b).	 The	
binding	 of	 Siglec‐3	 (p	<	0.001)	 is	 solely	 dependent	 on	 sialic	 acid.	
The	 binding	 of	 Siglec‐9	 (p	=	0.016)	 and	 Siglec‐14	 (p	=	0.004)	 was	
enhanced	 by	 sialic	 acid.	 However,	 residual	 binding	 suggested	 the	
presence	of	sialic	acid‐independent	ligands.	In	contrast,	the	binding	
of	Siglec‐16	to	F62	was	significantly	increased	(p	=	0.013)	in	the	ab‐
sence	of	sialic	acid.	Similar	results	were	observed	with	gonococcal	
strain	15253,	with	 the	exception	of	Siglec‐16,	where	sialylation	of	
15253	did	 not	 change	 the	 binding	 (Supporting	 Information	 Figure	
S6b).	Together	with	the	finding	in	Figures	1	and	2,	these	results	sup‐
port	the	hypothesis	that	structures	in	addition	to	sialic	acids	can	me‐
diate	the	interactions	of	Siglecs	and	gonococci.	It	is	possible	that	the	
glycan‐binding	pocket	that	confers	 lectin‐like	properties	to	Siglecs	
also	binds	to	other	glycan	structures.	To	elucidate	whether	Siglecs	
bind	 to	non‐sialylated	LOS	structures,	we	tested	Siglec	binding	by	
flow	 cytometry	 to	 isogenic	 mutants	 of	 strain	 F62	 that	 expressed	
truncated	 LOS	 glycans	 by	 (separately)	 inactivating	 the	 LOS	 glyco‐
syltransferases	 lgtD, lgtA, lgtE, and lgtF	 (Figure	 3a).	 Progressive	
truncation	 of	 LOS	 correlated	 with	 increased	 binding	 of	 Siglec‐5	
and	Siglec‐14	to	F62	(Figure	3c,f).	This	inverse	correlation	between	
Siglec	binding	and	LOS	glycan	length	was	not	significant	for	Siglec‐9	
(Figure	3d).	The	binding	of	Siglec‐11‐Fc	increases	significantly	with	
the	truncation	of	the	lactose	epitope	(Figure	3e).	Siglec‐16‐Fc	binds	
the	 strongest	 to	 the	mutant	with	 the	exposed	 (unsialylated)	 LNnT	
structure	(Figure	3g).	These	data	suggest	the	presence	of	an	alter‐
nate	ligand	on	N. gonorrhoeae	for	Siglecs.	When	present,	sialylated	
LOS	may	be	 the	primary	binding	 site	 for	LOS.	 In	contrast,	 as	with	
Siglec‐11	and	Siglec‐16,	sialylated	LNnT	LOS	may	actually	hinder	ac‐
cess	of	 the	 alternate	 ligand	 to	Siglecs.	However,	when	LOS	phase	
varies	 (e.g.,	 lgtA	 “off”),	 it	may	 leave	 the	 alternate	 ligand	more	 ex‐
posed	and	permit	binding	to	Siglecs.
F I G U R E  6  Activating	Siglecs	are	
protective.	Univariate	screen	of	females	
(a)	and	males	(b).	Additive	model	of	
females,	who	are	homozygous	for	
SIGLEC16	and	Siglec‐14	wt	(c)
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3.4 | Gonococcal Porin B mediates binding to 
human Siglecs in a protein‐dependent manner
In	addition	to	their	main	sialylated	ligands,	some	Siglecs	have	been	
reported	 to	 engage	 in	 protein–protein	 interactions	 (Carlin	 et	 al.,	
2009;	Fong	et	al.,	2015).	Porin	B	(PorB)	is	the	major	outer	membrane	
protein	 of	N. gonorrhoeae	 and	 is	 essential	 for	 gonococcal	 survival.	
We	 have	 shown	 previously	 that	 LOS	 structure	modulates	 binding	
of	 the	complement	 inhibitor	C4BP	to	PorB	 (Ram	et	al.,	2007).	We	
did	not	expect	the	unsialylated	glycans	expressed	by	the	gonococcal	
LOS	mutants	tested	in	Figure	3c‐g	above	to	directly	bind	to	Siglecs,	
but	 instead	explored	 the	possibility	 that	 alterations	 in	 LOS	glycan	
extensions	influenced	binding	of	Siglecs	to	PorB. We	tested	two	pu‐
rified	porins,	PorB.1A	purified	 from	the	strain	15253	and	PorB.1B	
derived	from	the	strain	F62	(Figure	4).	Neither	human	nor	chimpan‐
zee	Siglec‐3‐Fc	binds	to	PorB	molecules,	which	is	consistent	with	the	
finding	that	binding	of	human	Siglec‐3‐Fc	to	whole	bacteria	is	solely	
dependent	 on	 LOS	 sialic	 acid.	 PorB.1A	 and	 PorB.1B	 both	 bound	
only	to	human,	but	not	chimpanzee	Siglec‐5,	Siglec‐9,	and	Siglec‐14.	
Both	PorB	molecules	bound	to	human	and	chimpanzee	Siglec‐11	and	
Siglec‐16,	although	binding	to	chimpanzee	Siglecs	was	much	lower.	
The	 binding	 patterns	 of	 PorB.1A	 and	PorB.1B	were	 similar,	which	
could	 indicate	 a	 conserved	 binding	 region	 or	 motif	 between	 the	
two	porins.	The	preference	of	porins	to	bind	to	human	Siglecs	over	
chimpanzee	 homologs	 strengthens	 the	 hypothesis	 that	 gonococ‐
cal	 interactions	with	Siglecs	contribute	to	the	human	specificity	of	
gonorrhea.	It	is	worth	noting	that	in	some	instances,	whole	bacteria,	
but	not	the	respective	purified	PorB,	bound	to	chimpanzee	Siglecs.	
For	example,	F62	bound	to	cSiglec‐5,	cSiglec‐9,	and	cSiglec‐14,	and	
15,253	bound	to	cSiglec‐5	and	cSiglec‐14,	which	suggested	that	sur‐
face	molecules	other	than	PorB	might	engage	cSiglecs.
3.5 | Neisseria gonorrhoeae modulates innate 
immune response via engagement of Siglecs
The	innate	immune	system	plays	an	important	role	in	the	symptom‐
atology	of	 gonorrhea;	 the	 lack	of	 a	 robust	 inflammatory	 response	
contributes	to	the	 lack	of	symptoms	that	 is	commonly	seen,	espe‐
cially	 in	 women.	 Monocytes	 and	 macrophages	 are	 an	 important	
source	of	inflammatory	cytokines.	Multiple	attempts	to	establish	an	
immortalized	cell	 line	expressing	Siglec‐11	and	Siglec‐16	or	human	
monocytes	 as	model	 system	 failed.	 To	 investigate	whether	 Siglec	
interactions	with	N. gonorrhoeae	modulate	 the	 immune	 responses,	
we	used	a	monocytic	cell	line,	THP‐1,	which	was	stably	transfected	
with	the	paired	receptors	Siglec‐5	 (inhibitory)	or	Siglec‐14	(activat‐
ing)	(Yamanaka	et	al.,	2009),	as	a	model	system.	When	infected	with	
N. gonorrhoeae,	THP‐1	cells	expressing	Siglec‐5	expressed	lower	level	
of	IL‐6	compared	to	an	empty	vector	control	(p	=	0.046;	Figure	5a).	
F I G U R E  7  Possible	mechanism	
of	Siglec	gonococci	interactions.	
Neisseria gonorrhoeae engages human 
immunoregulatory	Siglec	receptors.	
Upon	binding,	the	inhibitory	receptors	
Siglec‐3,	Siglec‐5,	Siglec‐9	and,	Siglec‐11	
suppress	the	pro‐inflammatory	
response,	which	could	contribute	to	
decreased	clearance	of	infection	and	
overall	appearance	of	an	asymptomatic	
infection.	The	engagement	of	activating	
Siglec	receptors,	such	as	Siglec‐14	and	
Siglec‐16,	leads	to	an	activation	of	the	
pro‐inflammatory	signaling	cascade.	This	
can	contribute	to	a	better	clearance	of	a	
symptomatic	infection.	However,	these	
activating	receptors	are	expressed	only	
on	certain	individuals.	The	presence	of	
these	polymorphisms	could	contribute	to	
different	ability	of	clearing	a	gonococcal	
infection	among	individuals
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By	contrast,	expression	of	the	activating	Siglec‐14	increased	IL‐6	se‐
cretion	(p	=	0.043).	IL‐6	is	a	major	pro‐inflammatory	cytokine,	plays	
an	 important	 role	during	gonococcal	 infection,	and	 is	 found	 in	 the	
secretions	of	infected	patients	(Ramsey	et	al.,	1995).
In	addition	to	cytokine	secretion,	phagocytosis	is	a	common	re‐
sponse	to	fight	infections.	We	examined	the	phagocytic	activity	of	
THP‐1	cells	expressing	Siglec‐14	that	were	stimulated	with	purified	
PorB.1B.	 Increased	 phagocytic	 activity	 was	 seen	 when	 Siglec‐14‐
expressing	 THP‐1	 cells	 were	 incubated	 with	 PorB.1B	 (p	=	0.009).	
The	 addition	 of	 a	 Siglec‐14	blocking	 antibody	 reversed	 this	 effect	
(p	=	0.002),	 suggesting	 a	 functional	 interaction	 between	 Siglec‐14	
and	PorB	 is	a	direct	physical	contact	 (Figure	5b).	These	 results	 in‐
dicate	 that	 gonococcal	 engagement	 of	 inhibitory	 Siglecs	 such	 as	
Siglec‐5	 could	 contribute	 to	 inhibition	 of	 pro‐inflammatory	 re‐
sponses,	as	seen	 in	asymptomatic	disease.	On	the	other	hand,	en‐
gagement	of	activating	Siglecs,	such	as	Siglec‐14,	can	contribute	to	
the	 pro‐inflammatory	 response	 that	 could	 help	 clear	 gonococcal	
infection.
3.6 | Genetic polymorphisms in human Siglecs can 
influence burden of Neisseria gonorrhoeae
Similar	to	Siglec‐16,	Siglec‐14	is	also	not	expressed	in	every	individual	
(Yamanaka	et	al.,	2009).	The	absence	of	these	activating	receptors	
could	 contribute	 to	 asymptomatic	 disease	 and	 prolonged	 carriage	
of	 gonococci.	 The	 rs3865444	polymorphism	 in	 Siglec‐3	 could	 po‐
tentially	also	contribute,	as	it	leads	to	differential	expression	of	two	
Siglec‐3	isoforms	(Malik	et	al.,	2013).	The	C	allele	leads	to	high	ex‐
pression	of	the	full‐length	form	with	a	V‐set	sialic	acid‐binding	do‐
main,	which	can	bind	to	sialylated	gonococci,	whereas	the	A	allele	is	
associated	with	 lower	expression	of	 this	 isoform.	Therefore,	 the	C	
allele	potentially	reduces	pro‐inflammatory	responses	by	providing	
gonococci	with	more	exploitable	inhibitory	Siglec‐3	receptors.
To	 test	whether	 these	 genetic	 variations	 in	 human	 Siglecs	 are	
associated	with	gonococcal	 infections,	we	genotyped	a	human	co‐
hort	with	 a	 high	 burden	 of	 gonorrhea.	 A	 cross‐sectional	 study	 of	
Namibian	pastoralists	has	shown	that	over	64%	of	 the	tested	sex‐
ually	active	adult	population	is	infected	with	N. gonorrhoeae	with	a	
higher	prevalence	in	females	(72%)	compared	to	males	(57%;	Hazel	
et	al.,	2014).	 In	this	rural	population	where	partner	concurrency	 is	
normal	for	men	and	women,	gonorrhea	exposure	is	high	but	treat‐
ment	is	erratically	sought.
In	 this	 cohort,	 we	 found	 that	 infected	 females	 express	 the	
Siglec‐16	 receptor	 less	 frequently	with	 an	 allele	 frequency	 of	 the	
SIGLEC16	with	 0.155	 compared	 to	 uninfected	women	with	 0.213	
(Supporting	Information	Table	S1).	We	further	found	trends	showing	
higher	expression	of	activating	Siglec‐14	receptor	expressed	in	the	
uninfected	population	with	an	allele	frequency	of	0.729	compared	to	
0.693	in	the	infected	population.	If	statistically	significant,	this	trend	
could	support	our	hypothesis	that	activating	Siglec‐14	is	protective.	
We	saw	a	similar	trend	when	females	and	males	were	analyzed	sep‐
arately.	The	pathology	of	the	gonococcal	infection	is	very	different	
between	males	and	 females,	and	 therefore,	 it	 is	 important	 to	 look	
at	the	two	populations	separately.	There	were	no	significant	differ‐
ences	between	the	A	and	C	alleles	 in	Siglec‐3	among	 infected	and	
uninfected	persons.
To	test	the	statistical	significance	of	these	observations,	we	used	
a	univariate	logistic	regression	screen	within	the	female	population	
and	 found	a	significant	protective	association,	odds	 ratio	of	0.092	
(p	=	0.034;	95%	confidence	interval	(CI)	=	0.005–0.636),	for	women	
with	the	homozygous	genotype	for	Siglec‐16	(Figure	6a,	Supporting	
Information	Table	S2).	The	same	analysis	showed	no	significant	pro‐
tection	or	 risk	 for	 the	different	genotypes	 in	males	 (Figure	6b).	 In	
an	 additive	 model	 of	 homozygous	 Siglec‐14	 wt	 and	 Siglec‐16	 wt,	
Siglec‐16	 again	 showed	 again	 significant	 protection	 with	 an	 odds	
ratio	 of	 0.089	 (p	=	0.032;	 CI	=	0.004–0.620);	 however,	 Siglec‐14	
alone	was	 not	 significant,	 with	 an	 odds	 ratio	 of	 0.713	 (p = 0.280; 
CI	=	0.384–1.318;	Figure	6c,	Supporting	Information	Table	S2).
It	is	possible	that	the	greater	significance	of	the	Siglec‐16	geno‐
type	may	result	because	Siglec‐16	is	expressed	on	macrophages	and	
also	on	the	cervical	epithelium,	which	is	the	main	site	of	 infection.	
This	additional	site	of	expression	could	enhance	contact	with	gono‐
cocci	and	thus	drive	selection	for	the	protective	Siglec‐16	genotype.	
It	is	worth	noting	that	immortalized	cervical	epithelial	cells	also	re‐
lease	pro‐inflammatory	cytokines	following	stimulation	with	N. gon‐
orrhoeae	(Fichorova,	Desai,	Gibson,	&	Genco,	2001).
4  | DISCUSSION
Neisseria gonorrhoeae	 has	 evolved	 a	 variety	 of	 strategies	 to	 infect	
the	human	host	and	exploit	its	immune	system	(Edwards	&	Apicella,	
2004).	In	this	study,	we	present	a	new	mechanism	whereby	N. gonor‐
rhoeae engages	human	Siglec	 receptors	 to	suppress	pro‐inflamma‐
tory	signaling.	Natural	infection	with	N. gonorrhoeae	is	restricted	to	
humans.	In	the	1970s,	a	urethral	model	of	gonorrhea	in	male	chim‐
panzees	(Pan troglodytes)	was	established	(Arko,	1989).	Infection	oc‐
curred	by	some,	but	not	all	strains	of	N. gonorrhoeae	(Arko,	Duncan,	
Brown,	Peacock,	&	Tomizawa,	1976;	Kraus,	Brown,	&	Arko,	1975).	
Similar	to	humans,	localized	urethral	infection	in	chimpanzees	lasted	
from	3	to	6	weeks	 (Lucas,	Chandler,	Martin,	&	Schmale,	1971)	and	
male‐to‐female	transmission	among	sexually	active	cage	mates	was	
documented	(Brown,	Lucas,	&	Kuhn,	1972).	Several	reasons	for	the	
natural	host	restriction	of	gonococcal	infection	have	been	elucidated,	
including	 specificity	 for	human	CEACAMs	 (Pils,	Gerrard,	Meyer,	&	
Hauck,	2008;	Sadarangani,	Pollard,	&	Gray‐Owen,	2011;	Sintsova	et	
al.,	 2015;	 Voges,	 Bachmann,	 Kammerer,	Gophna,	&	Hauck,	 2010),	
the	ability	to	utilize	transferrin	as	an	iron	source	from	humans	and	
only	 certain	non‐human	primates	 (Gray‐Owen	&	Schryvers,	 1993)	
and	 the	 inability	 to	 evade	 non‐human	 complement	 because	 of	 its	
selective	binding	to	the	human	complement	inhibitors,	factor	H	and	
C4b‐binding	 protein	 (C4BP)	 (Ngampasutadol	 et	 al.,	 2005,	 2008).	
Our	results	show	that	N. gonorrhoeae	binds	preferentially	to	human	
Siglecs,	which	may	be	another	reason	for	its	human	specificity.
Apart	 from	 these	 evolutionary	 considerations,	 the	 data	 pre‐
sented	in	this	work	suggest	that	interaction	of	N. gonorrhoeae with	
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Siglecs	 plays	 a	 role	 in	 the	 innate	 immune	 response	 during	 infec‐
tion	(see	summary	in	Figure	7).	Binding	to	the	inhibitory	receptors	
Siglec‐3,	Siglec‐5,	Siglec‐9,	and	Siglec‐11	suppresses	the	pro‐inflam‐
matory	response,	which	could	contribute	to	decreased	clearance	of	
infection	and	 contribute	 to	 the	 relative	paucity	of	 symptoms.	The	
engagement	 of	 activating	 Siglec	 receptors,	 such	 as	 Siglec‐14	 and	
Siglec‐16,	 leads	 to	 an	 activation	of	 the	pro‐inflammatory	 signaling	
cascade	that	facilitates	clearance	of	gonococcal	infection.	However,	
these	activating	receptors	are	not	present	on	all	 individuals,	which	
may	 account,	 at	 least	 in	 part,	 for	 differences	 across	 individuals	 in	
their	ability	to	clear	gonococcal	infections.
The	 role	 of	 pro‐inflammatory	 responses	 in	 gonococcal	 patho‐
genesis	 remains	 controversial	 (Criss	 &	 Seifert,	 2012;	 Virji,	 2009).	
While	activating	receptors	such	as	Siglec‐14	and	Siglec‐16	may	con‐
tribute	to	a	pro‐inflammatory	response	following	infection	facilitate	
clearance	 of	 infection,	 N. gonorrhoeae	 have	 developed	 numerous	
mechanisms	to	survive	within	neutrophils	that	are	abundant	at	the	
site	 of	 infection	 upon	 pro‐inflammatory	 stimuli,	which	 could	 form	
a	“safe	haven”	for	bacteria	(Criss	&	Seifert,	2012).	Multiple	factors,	
such	as	sex	and	site	of	infection,	play	a	role	in	the	effectiveness	of	
a	pro‐inflammatory	stimulus.	The	genetic	analysis	of	the	Namibian	
pastoralists	shows	that	 the	presence	of	activating	Siglec‐16	 is	cor‐
related	with	 a	 lower	 burden	 of	 gonorrhea	 in	 females.	 Siglec‐16	 is	
expressed	by	cervical	epithelium	 in	addition	 to	 immune	cells,	 thus	
making	it	an	activating	Siglec	that	gonococci	are	likely	to	encounter	
in	the	early	stages	of	infection.	This	could	explain	why	Siglec‐16	has	
stronger	effect	on	the	gonococcal	burden	compared	to	the	activat‐
ing	Siglec‐14,	which	 is	only	expressed	on	neutrophils.	 It	 is	 intrigu‐
ing	 that	 unsialylated	N. gonorrhoeae	 bind	 better	 to	 Siglec‐16	 than	
sialylated	bacteria.	Ketterer	et	al.	(2016)	recently	showed	that	siali‐
dases	are	present	in	the	female	genital	tract	in	amounts	sufficient	to	
desialylate	gonococcal	LOS	and	enhance	 infectivity	 in	men,	where	
unsialylated	gonococci	can	engage	 the	asialoglycoprotein	 receptor	
(ASGP‐R;	Harvey	et	 al.,	 2001).	 The	 ability	of	 Siglec‐16	 to	 respond	
to	 unsialylated	 gonococci	 may	 represent	 an	 evolutionary	 mech‐
anism	 that	 permits	 the	host	 to	 adapt	 to	 gonococci	whose	 surface	
has	been	modified	by	sialidases	elaborated	by	cohabiting	microbial	
flora	 (Ketterer	 et	 al.,	 2016).	 Ascending	 gonococcal	 infections	 can	
also	cause	pelvic	 inflammatory	disease,	a	major	cause	of	 infertility	
(Gradison,	2012)	(Reekie	et	al.,	2017).	Whether	interactions	between	
N. gonorrhoeae	and	Siglecs	contribute	to	pelvic	inflammatory	disease	
and	infertility	merits	further	study.	Any	impact	on	fertility	would	be	
a	powerful	driver	of	selection	for	SIGLEC	gene	polymorphisms.
On	a	more	general	note,	we	and	others	have	reported	how	the	
human	specificity	of	certain	infectious	diseases	such	as	Salmonella 
typhi‐mediated	 typhoid	 fever	 and	Plasmodium falciparum malaria 
might	 be	 explained	 by	 the	 human‐universal	 genetic	 loss	 of	 the	
common	mammalian	sialic	acid	Neu5Gc	(Deng	et	al.,	2014;	Martin,	
Rayner,	Gagneux,	Barnwell,	&	Varki,	2005).	These	organisms	have	
evolved	modification	of	certain	binding	proteins	to	preferentially	
recognize	the	precursor	sialic	acid	Neu5Ac,	which	accumulates	in	
excess	 in	 humans.	While	 no	pathogens	 are	 known	 to	 synthesize	
Neu5Gc,	 other	 human	 pathogens	 have	 independently	 evolved	
convergent	ways	to	coat	themselves	with	Neu5Ac	containing	gly‐
cans,	 and	 thereby	 evade	 the	 innate	 immune	 response	 via	multi‐
ple	 mechanisms,	 including	 the	 engagement	 of	 inhibitory	 Siglecs	
on	 innate	 immune	cells	 (Chang	&	Nizet,	2014;	Varki	&	Gagneux,	
2012;	 Vimr,	 Kalivoda,	 Deszo,	 &	 Steenbergen,	 2004).	 Two	 such	
documented	examples	include	human‐specific	pathogens	group	B	
streptococcus	which	engages	Siglec‐9	on	neutrophils	and	Siglec‐5	
on	 the	 amniotic	 epithelium	 (Ali	 et	 al.,	 2014;	 Carlin	 et	 al.,	 2007)	
and E. coli	K‐1	which	 engages	Siglec‐11	on	brain	microglia,	 likely	
suppressing	their	microbicidal	activity	during	the	process	of	caus‐
ing	meningitis	 (Schwarz	et	al.,	2017).	Here,	we	report	a	different	
evolutionary	strategy	for	human	specificity,	employed	by	a	bacte‐
rium,	which	 largely	bypasses	the	sialic	acid‐binding	properties	of	
Siglecs	and	instead	engages	them	directly	via	protein–protein	in‐
teractions.	The	other	pathogen	in	the	genus	Neisseria,	N. meningit‐
idis,	also	engages	Siglec‐1	and	Siglec‐5	which	results	in	increased	
bacterial	 phagocytosis;	 however,	 the	 interaction	occurred	exclu‐
sively	through	sialylated	lacto‐N‐neotetraose	LOS	(Jones,	Virji,	&	
Crocker,	2003).
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